Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 8:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diabetes Mellitus, Experimental Clear all
Completed Not applicable Interventional Results available

Evaluation of an Karajishi TS Investigational Blood Glucose Monitoring System

NCT02041377
View directory record Official record
Conditions
Diabetes
Interventions
Karajishi TS Investigational Blood Glucose Monitoring System
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Escondido, California • Renton, Washington
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Jul 24, 2026, 8:50 AM EDT
Completed Phase 3 Interventional

A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics

NCT00067951
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
rosiglitazone/metformin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
49
States / cities
Anniston, Alabama • Chandler, Arizona • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Jul 24, 2026, 8:50 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis

NCT00612014
View directory record Official record
Conditions
Gastroparesis, Diabetes Mellitus
Interventions
5% dextrose in water, TZP-101
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
San Francisco, California • Anderson, Indiana • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Jul 24, 2026, 8:50 AM EDT
Recruiting Phase 1 Interventional

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

NCT05142189
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
BNT116, Cemiplimab, Docetaxel, Carboplatin, Paclitaxel, BNT316, anti-B7-H3 antibody conjugated to topoisomerase I inhibitor, anti-HER3 antibody conjugated to topoisomerase I inhibitor, Bispecific antibody for PD-L1 and VEGF-A, Osimertinib, ALK-inhibitor or RET-inhibitor
Biological · Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
6
States / cities
Lexington, Kentucky • Louisville, Kentucky • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 24, 2026, 8:50 AM EDT
Completed Not applicable Interventional Results available

Study of an Investigational Glucose Meter System

NCT01466075
View directory record Official record
Conditions
Diabetes
Interventions
Apollo Evolution Investigational BG Monitoring System
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Mishawaka, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Jul 24, 2026, 8:50 AM EDT
Completed Phase 2 Interventional Results available

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

NCT01517373
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, PF-04937319 10 mg, PF-04937319 50 mg, PF-04937319 100 mg, Glimepiride
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Roseville, California • San Diego, California • Walnut Creek, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Jul 24, 2026, 8:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of a Noninvasive Diabetes Screening Device in Subjects at Risk for Diabetes

NCT01080157
View directory record Official record
Conditions
Diabetes
Interventions
SCOUT DS measurement
Device
Lead sponsor
VeraLight, Inc.
Industry
Eligibility
18 Years and older
Enrollment
509 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
12
States / cities
Huntsville, Alabama • San Diego, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Jul 24, 2026, 8:50 AM EDT
Active, not recruiting No phase listed Observational

Intestinal Metabolic Reprogramming as a Key Mechanism of Gastric Bypass in Humans

NCT02710370
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Type 2, Endocrine System Diseases, Glucose Metabolism Disorders, Metabolic Diseases
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 24, 2026, 8:50 AM EDT
Completed Not applicable Interventional Results available

Performance of an Investigational Blood Glucose Monitoring System

NCT01824355
View directory record Official record
Conditions
Diabetes
Interventions
Ninja 3 PLUS Investigational BG Monitoring System
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Jul 24, 2026, 8:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of a Ascensia ONYX NEXT Investigational Blood Glucose Monitoring System

NCT02390167
View directory record Official record
Conditions
Diabetes
Interventions
ONYX NEXT BGMS
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Escondido, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Jul 24, 2026, 8:50 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

NCT03495102
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,842 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
72
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Jul 24, 2026, 8:50 AM EDT
Completed Not applicable Interventional Results available

Performance Evaluation of an Investigational Blood Glucose Monitoring System

NCT01598610
View directory record Official record
Conditions
Diabetes
Interventions
CONTOUR® PLUS Investigational BG Monitoring System
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Indianapolis, Indiana • Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Jul 24, 2026, 8:50 AM EDT
Completed Not applicable Interventional Results available

User Performance Evaluation of an Investigational Blood Glucose Monitoring System

NCT01410773
View directory record Official record
Conditions
Diabetes
Interventions
Ninja 2 Investigational Blood Glucose Monitoring System
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Mishawaka, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Jul 24, 2026, 8:50 AM EDT
Completed Phase 2 Interventional Results available

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

NCT03751657
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Placebo (insulin 287), Metformin, Dipeptidyl peptidase-4 inhibitors, Insulin glargine, Placebo (insulin glargine)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
Lancaster, California • Ventura, California • Walnut Creek, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Jul 24, 2026, 8:50 AM EDT
Completed Phase 2 Interventional Results available

A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

NCT03969719
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
Placebo, PF-06835919
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
86
States / cities
Gilbert, Arizona • Tempe, Arizona • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Jul 24, 2026, 8:50 AM EDT
Withdrawn Not applicable Interventional

Single Site, Single Subject, Treatment IND With Mannkind Corporation's Technosphere Inhalation System

NCT01459133
View directory record Official record
Conditions
Diabetes
Interventions
Technosphere® Insulin Inhalation System
Drug
Lead sponsor
South Orange County Endocrinology
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Jul 24, 2026, 8:50 AM EDT
Completed Not applicable Interventional

Developing an Adaptive Lifestyle Intervention Program in Family Medicine Clinics

NCT04392284
View directory record Official record
Conditions
Insulin Resistance, Obesity, Diabetes, Hypertension, Dyslipidemias, Metabolic Syndrome
Interventions
Diet Counseling, Exercise Counseling
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Jul 24, 2026, 8:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Roles of Trust and Respect in Patient Reactions to Race-based and Personalized Medicine Vignettes: An Experimental Study

NCT00911833
View directory record Official record
Conditions
Diabetes, Congenital Heart Disease, Hypertension
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 24, 2026, 8:50 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

NCT03013491
View directory record Official record
Conditions
Solid Tumor, Lymphoma
Interventions
CX-072, ipilimumab, vemurafenib
Drug
Lead sponsor
CytomX Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Jul 24, 2026, 8:50 AM EDT
Completed Phase 1 Interventional

Experimental Study to Validate the Modified Glucose Disposal Test

NCT01152372
View directory record Official record
Conditions
Diabetes
Interventions
Insulin, glucose and staple isotopes
Procedure
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2011 · Synced Jul 24, 2026, 8:50 AM EDT
Completed Phase 2Phase 3 Interventional

Dextrose Gel Does Not Prevent Neonatal Hypoglycemia

NCT02523222
View directory record Official record
Conditions
Hypoglycemia, Infant, Small for Gestational Age, Premature Birth of Newborn, Fetal Macrosomia, Intrauterine Growth Restriction, Complication of Prematurity, Neonatal Hypoglycemia
Interventions
40% Dextrose gel
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
0 Hours to 1 Hour
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Jul 24, 2026, 8:50 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

NCT06037252
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Phoenix, Arizona • Concord, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jul 24, 2026, 8:50 AM EDT
Terminated Not applicable Interventional Results available

A Comparison of an Investigational Dressing to Tegaderm Matrix Wound Dressing in the Management of Diabetic Foot Ulcers

NCT01013792
View directory record Official record
Conditions
Foot Ulcer, Diabetic
Interventions
Wound Dressing
Device
Lead sponsor
Solventum US LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
6
States / cities
Montgomery, Alabama • Castro Valley, California • Bay Pines, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Jul 24, 2026, 8:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of an Karajishi Contour Investigational Blood Glucose Monitoring System (ISO/FDA Study)

NCT02150109
View directory record Official record
Conditions
Diabetes
Interventions
Subjects WITH/WITHOUT Diabetes Use Karajishi Contour BGMS, Subjects WITH Diabetes Use Karajishi Contour BGMS
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Escondido, California • Renton, Washington
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Jul 24, 2026, 8:50 AM EDT